Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer

In this study, we investigated host response to Bacillus-Calmette Guérin (BCG) immunotherapy using the murine MM45T bladder tumor cell line. BALB/c (Bcgs allele) and BALB/c.CD2 (CD2) (Bcgr allele) mice were seeded subcutaneously with MM45T cells. Treatment began on day 7 with intra-tumor injections...

Full description

Bibliographic Details
Main Authors: Hakeem Sam, Mary M Stevenson
Format: Article
Language:English
Published: McGill University 2020-12-01
Series:McGill Journal of Medicine
Subjects:
Online Access:https://mjm.mcgill.ca/article/view/755
_version_ 1819054732459638784
author Hakeem Sam
Mary M Stevenson
author_facet Hakeem Sam
Mary M Stevenson
author_sort Hakeem Sam
collection DOAJ
description In this study, we investigated host response to Bacillus-Calmette Guérin (BCG) immunotherapy using the murine MM45T bladder tumor cell line. BALB/c (Bcgs allele) and BALB/c.CD2 (CD2) (Bcgr allele) mice were seeded subcutaneously with MM45T cells. Treatment began on day 7 with intra-tumor injections of BCG. Significant decreases in tumor growth in BALB/c (p < 0.05) but not in the CD2 (p = NS) mice were observed 6, 10 and 14 days following treatment. Investigation of the mechanism(s) underlining the difference in the response between the two strains of mice revealed key points, namely: (i) Intraperitoneal injection of BCG led to a significant increase (p < 0.05) in the number of cells recovered 14 days later by peritoneal lavage (in million cells: 5.1 ± 0.7 vs 9.5 ± 0.3 in BALB/c and 5.3 ± 0.4 vs 7.0 ± 0.4 in CD2, PBS vs BCG). (ii) Compositional analysis of the lavages following BCG injection indicated a significant increase in the lymphocyte/macrophage ratio in BALB/c mice as compared to CD2 mice (p < 0.05). (iii) Activated peritoneal macrophage production of nitric oxide (NO) was significantly lower (p < 0.05) in BALB/c than in CD2 (26.8 ± 1.6 vs 38.3 ± 0.7 uM of nitrite respectively) when challenged with lipopolysaccharide. (iv) No difference in the in vitro cytotoxicity against MM45T cells was observed between BALB/c and CD2 macrophages. Our results suggest that differences in the composition of monocytes infiltrating the site of BCG treatment and in the release of substances such as NO by macrophages may be key determinants of the response to BCG immunotherapy for bladder cancer.
first_indexed 2024-12-21T12:56:18Z
format Article
id doaj.art-f9734bd71106492a9226d01e2b633c09
institution Directory Open Access Journal
issn 1715-8125
language English
last_indexed 2024-12-21T12:56:18Z
publishDate 2020-12-01
publisher McGill University
record_format Article
series McGill Journal of Medicine
spelling doaj.art-f9734bd71106492a9226d01e2b633c092022-12-21T19:03:20ZengMcGill UniversityMcGill Journal of Medicine1715-81252020-12-011110.26443/mjm.v1i1.755970Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder CancerHakeem SamMary M StevensonIn this study, we investigated host response to Bacillus-Calmette Guérin (BCG) immunotherapy using the murine MM45T bladder tumor cell line. BALB/c (Bcgs allele) and BALB/c.CD2 (CD2) (Bcgr allele) mice were seeded subcutaneously with MM45T cells. Treatment began on day 7 with intra-tumor injections of BCG. Significant decreases in tumor growth in BALB/c (p < 0.05) but not in the CD2 (p = NS) mice were observed 6, 10 and 14 days following treatment. Investigation of the mechanism(s) underlining the difference in the response between the two strains of mice revealed key points, namely: (i) Intraperitoneal injection of BCG led to a significant increase (p < 0.05) in the number of cells recovered 14 days later by peritoneal lavage (in million cells: 5.1 ± 0.7 vs 9.5 ± 0.3 in BALB/c and 5.3 ± 0.4 vs 7.0 ± 0.4 in CD2, PBS vs BCG). (ii) Compositional analysis of the lavages following BCG injection indicated a significant increase in the lymphocyte/macrophage ratio in BALB/c mice as compared to CD2 mice (p < 0.05). (iii) Activated peritoneal macrophage production of nitric oxide (NO) was significantly lower (p < 0.05) in BALB/c than in CD2 (26.8 ± 1.6 vs 38.3 ± 0.7 uM of nitrite respectively) when challenged with lipopolysaccharide. (iv) No difference in the in vitro cytotoxicity against MM45T cells was observed between BALB/c and CD2 macrophages. Our results suggest that differences in the composition of monocytes infiltrating the site of BCG treatment and in the release of substances such as NO by macrophages may be key determinants of the response to BCG immunotherapy for bladder cancer.https://mjm.mcgill.ca/article/view/755bladder cancergeneticsbcgimmunotherapy
spellingShingle Hakeem Sam
Mary M Stevenson
Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
McGill Journal of Medicine
bladder cancer
genetics
bcg
immunotherapy
title Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
title_full Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
title_fullStr Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
title_full_unstemmed Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
title_short Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
title_sort mechanism of genetically regulated response to bacillus calmette guerin immunotherapy for bladder cancer
topic bladder cancer
genetics
bcg
immunotherapy
url https://mjm.mcgill.ca/article/view/755
work_keys_str_mv AT hakeemsam mechanismofgeneticallyregulatedresponsetobacilluscalmetteguerinimmunotherapyforbladdercancer
AT marymstevenson mechanismofgeneticallyregulatedresponsetobacilluscalmetteguerinimmunotherapyforbladdercancer